Loading...
OTCM
QBIO
Market cap14kUSD
May 22, Last price  
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-100.00%
IPO
-100.00%
Name

Q BioMed Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
284k
+45.38%
000000030,000195,597284,352
Net income
-716k
L-91.81%
-500-38,050-1,086,617-7,171,511-14,541,667-9,270,777-11,740,114-13,788,406-8,747,472-716,095
CFO
2m
P
0-37,351-91,392-1,545,259-5,584,451-6,450,621-4,105,027-6,233,441-4,302,0361,941,404

Profile

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
URL
https://qbiomed.com/
IPO date
Nov 17, 2014
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
284
45.38%
Cost of revenue
3,730
Unusual Expense (Income)
NOPBT
(3,446)
NOPBT Margin
Operating Taxes
(1,336)
Tax Rate
NOPAT
(2,110)
Net income
(716)
-91.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
120
BB yield
-16.76%
Debt
Debt current
4,110
Long-term debt
Deferred revenue
Other long-term liabilities
(1)
Net debt
917
Cash flow
Cash from operating activities
1,941
CAPEX
Cash from investing activities
(3,143)
Cash from financing activities
908
FCF
(119)
Balance
Cash
50
Long term investments
3,143
Excess cash
3,179
Stockholders' equity
(60,926)
Invested Capital
60,418
ROIC
ROCE
679.02%
EV
Common stock shares outstanding
44,757
Price
0.02
-96.46%
Market cap
716
-94.09%
EV
6,718
EBITDA
(3,396)
EV/EBITDA
Interest
1,384
Interest/NOPBT